Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan

Food and Chemical Toxicology

Volumn 47, Issue 10, 2009, Pages 2445-2449

  Lialiaris, Th S ^a   Kotsiou, E ^a   Pouliliou, S ^a   Kareli, D ^a   Makrinou, H ^a   Kouskoukis, A ^a   Papachristou, F ^a   Koukourakis, M ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Amifostine; Cultured lymphocytes; Irinotecan; Mitotic index; Sister Chromatid Exchanges

Indexed keywords

AMIFOSTINE; IRINOTECAN;

ADULT; ARTICLE; CELL DIVISION; CELL PROTECTION; CHROMOSOME DAMAGE; CONTROLLED STUDY; CYTOGENETICS; DRUG ACTIVITY; DRUG EXPOSURE; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYMPHOCYTE; MALE; MITOSIS; SISTER CHROMATID EXCHANGE;

ADOLESCENT; ADULT; AMIFOSTINE; ANTIMUTAGENIC AGENTS; CAMPTOTHECIN; CELL PROLIFERATION; CELLS, CULTURED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; ENZYME INHIBITORS; HUMANS; LYMPHOCYTES; MALE; MITOTIC INDEX; RADIATION-PROTECTIVE AGENTS; SISTER CHROMATID EXCHANGE; YOUNG ADULT;

EID: 69549114298     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2009.06.042     Document Type: Article

References (38)

1. Blasiak J., Gloc E., Pertynski T., and Drzewoski J. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine. Anti-Cancer Drug. 13 (2002) 1055-1060
2. Brogger A. Application of SCE to public health. In: Sandberg A.A. (Ed). Sister Chromatid Exchanges (1982), Alan R. Liss Inc., NY 655-674
3. Capizzi R.L., and Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int. J. Hematol. 72 (2000) 425-435
4. Carrano A.V., Thompson L.H., Lindl P.A., and Minkler J.L. Sister chromatid exchange as an indicator of mutagenesis. Nature 271 (1978) 551-553
5. Dai D., Holmes A.M., Nguyen T., Davies S., Theele D.P., Verschraegen C., and Leslie K.K. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res. 65 (2005) 9517-9524
6. Deen D., Kendall L., Marton L., and Tofilon P.J. Prediction of tumor cell chemosensitivity using the sister chromatid exchange assay. Cancer Res. 46 (1986) 1599-1602
7. Degrassi F., De Salvia R., Tanzarella C., and Palitti F. Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mut. Res. 211 (1989) 125-130
8. Delioukina M.L., Prager D., Parson M., Hecht J.R., Rosen P., and Rosen L.S. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 94 (2002) 2174-2179
9. Fousteris M., Koutsourea A., Arsenou E., Papageorgiou A., Mourelatos D., and Nikolaropoulos S. Structure-anti-leukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil. Anti-Cancer Drug. 17 (2006) 511-519
10. Giatromanolaki A., Sivridis E., Maltezos E., and Koukourakis M.I. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin. Oncol. 29 (2002) 14-21
11. Goto K., Maeda S., Kano Y., and Suguyama T. Factors involved in differential Giemsa staining of sister-chromatids. Chromosoma 66 (1978) 351-359
12. Hartmann J.T., Knop S., Fels L.M., van Vangerow A., Stolte H., Kanz L., and Bokemeye C. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anti-Cancer Drug. 11 (2000) 1-6
13. Hofheinz R.D., Gnad-Vogt U., Wein A., Saussele S., Kreil S., Pilz L., Hehlmann R., and Hochhaus A. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anti-Cancer Drug. 16 (2005) 39-45
14. Holwitt E.A., Koda E., and Swenberg C.E. Enhancement of toposiomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278. Rad. Res. 124 (1990) 107-109
15. Kojima A., Shinkai T., and Saijo N. Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. Jpn. J. Clin. Oncol. 2 (1993) 116-122
16. Koukourakis M.I. Amifostine in clinical oncology: current use and future applications. Anti-Cancer Drug. 13 (2002) 181-209
17. Koukourakis M.I., Simopoulos C., Minopoulos G., Patlakas G., Polychronidis A., Limberis V., Romanides K., Pitiacoudis M., and Manolas C. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin. Cancer Res. 9 (2003) 3288-3293
18. Latt S.A., Schreck R.R., D' Andrea A., Kaiser T.N., Schlesinger F., Lester S., et al. Detection, significance and mechanism of SCE formation: past experiments, current concepts, future challenges. In: Tice R.R., and Hollaender A. (Eds). SCE Part A: The Nature of SCEs (1984), PI Press, NY 11-40
19. Lee E.J., Gerhold M., Palmer M.W., and Christen R.D. P53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br. J. Cancer 88 (2003) 754-759
20. Lialiaris T., Mourelatos D., Boutis L., Papageorgiou A., Christianopoulou M., Papageorgiou V., and Dozi-Vassiliades J. Comparative-study on cytogenesis effects by dislpatinum complexes of the ligands of naphthazarine and squaric acid in human-lymphocytes. J. Pharmacol. Exp. Therap. 24 (1989) 368-371
21. Lialiaris T., Mourelatos D., Stergiadou H.C., and Constantinidou H.A. Cytogenesis study for possible mutagenesis activity induced by ice-nucleation bacteria or their metabolic products in humans-lymphocytes in vitro. Mut. Res. 242 (1990) 163-168
22. Lialiaris T., Pantazaki A., Sivridis E., and Mourelatos D. Chloropromazine-induced damage on nucleic acids: a combined cytogenetic and biochemical study. Mut. Res. 265 (1992) 155-163
23. Lialiaris T., Pantazaki A., Papachrisou F., Lyrantzopoulos E., Natsis K., and Kortsaris A. The mutagenesis potential of vitamin C on human lymphocytes and native nucleoid acids. J. Biol. Res. - Thessaloniki 8 (2007) 189-197
24. Lialiaris T., Lyratzopoulos E., Papachrisou F., Simopoulou M., Mourelatos C., and Nikolettos N. Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of malpalan. Mutagenesis 23 (2008) 347-354
25. Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M., and Sim S.P. Mechanism of action of camptothecin. Annal. NY Acad. Sci. 922 (2000) 1-10
26. Maskaleris T., Lialiaris T., and Triantaphyllidis C. Induction of cytogenetic damage in human lymphocytes in vitro and of antineoplastic effects in Ehrlich ascites tumor cells in vivo treated by methotrexate, hypothermia and/or caffeine. Mut. Res. 422 (1998) 229-236
27. Mathijssen R.H., Loos W.J., Verweij J., and Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2 (2002) 103-123
28. Michelutti A., Stocchi R., Cardoni A., Tiribelli M., Calistri E., Russo D., Fanin R., and Damiani D. Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells. Cancer Chemothr. Pharmacol. 57 (2006) 517-524
29. Mpountoukas P., Vantarakis A., Sivridis E., and Lialiaris T. Cytogenesis study in culture human lymphocytes treated with three commonly used preservatives. Food Chem. Toxicol. 46 (2008) 2390-2393
30. North S., El-Ghissassi F., Pluquet O., Verhaegh G., and Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19 (2000) 1206-1214
31. Pantazaki A., and Lialiaris T. Combined biochemical and cytogenetic study of thioridazine-induced damage on nucleic acids. Mutagenesis 14 (1999) 243-248
32. Perry P., and Evans H. Cytological detection of mutagen-carcinogen exposure by sister chromatid exchange. Nature 258 (1975) 121-125
33. Pizzolato J.F., and Saltz L.B. The camptothecins. Lancet 361 (2003) 2235-2242
34. Rothenberg M.L., Kuhn J.G., Burris III H.A., Nelson J., Eckardt J.R., Tristan-Morales M., Hilsenbeck S.G., Weiss G.R., Smith L.S., and Rodriguez G.I. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11 (1993) 2194-2204
35. Shimada Y., Yoshino M., Wakui A., Nakao I., Futatsuki K., Sakata Y., Kambe M., Taguchi T., and Ogawa N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. 11 (1993) 909-913
36. Solomon E., and Bobrow M. Sister Chromatid Exchanges - a sensitive assay of agents damaging human chromosomes. Mut. Res. 30 (1975) 273-278
37. Souid A.K., Dubowy R.L., Blaney S.M., Hershon L., Sullivan J., McLeod W.D., and Bernstein M.L. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin. Cancer Res. 9 (2003) 703-710
38. Tofilon P.J., Basic I., and Milas L. Prediction of in vivo tumour response to chemotherapeutic agents by the in vitro sister chromatid exchange assay. Cancer Res. 45 (1985) 2025-2030